The　emerging　monkeypox　virus　(MPXV)　is　a　zoonotic　orthopoxvirus　that　causes　infections　in　humans　similar　to　smallpox.　Since　May　2022,　cases　of　monkeypox　(MPX)　have　been　increasingly　reported　by　the　World　Health　Organization　(WHO)　worldwide.　Currently,　there　are　no　clinically　validated　treatments　for　MPX　infections.　In　this　study,　an　immunoinformatics　approach　was　used　to　identify　potential　vaccine　targets　against　MPXV.　A　total　of　190　MPXV-2022　proteins　were　retrieved　from　the　ViPR　database　and　subjected　to　various　analyses　including　antigenicity,　allergenicity,　toxicity,　solubility,　IFN-gamma,　and　virulence.　Three　outer　membrane　and　extracellular　proteins　were　selected　based　on　their　respective　parameters　to　predict　B-cell　and　T-cell　epitopes.　The　epitopes　are　conserved　among　different　strains　of　MPXV　and　the　population　coverage　is　100%　worldwide,　which　will　provide　broader　protection　against　various　strains　of　the　virus　globally.　Nine　overlapping　MHC-I,　MHC-II,　and　B-cell　epitopes　were　selected　to　design　multi-epitope　vaccine　constructs　linked　with　suitable　linkers　in　combination　with　different　adjuvants　to　enhance　the　immune　responses　of　the　vaccine　constructs.　Molecular　modeling　and　structural　validation　ensured　high-quality　3D　structures　of　vaccine　constructs.　Based　on　various　immunological　and　physiochemical　properties　and　docking　scores,　MPXV-V2　was　selected　for　further　investigation.　In　silico　cloning　revealed　a　high　level　of　gene　expression　for　the　MPXV-V2　vaccine　within　the　bacterial　expression　system.　Immune　and　MD　simulations　confirmed　the　molecular　stability　of　the　MPXV-V2　construct,　with　high　immune　responses　within　the　host　cell.　These　results　may　aid　in　the　development　of　experimental　vaccines　against　MPXV　with　increased　potency　and　improved　safety.